Study results demonstrate that ProBiotix’s probiotic strain can significantly reduce low-density lipoprotein levels.
ProBiotix Health, a subsidiary of OptiBiotix Health, has released new scientific evidence that its patented probiotic strain Lactobacillus plantarum LPLDL can significantly reduce low-density lipoprotein [LDL] cholesterol levels, a key biomarker associated with increased coronary heart disease (CHD) risk.
The placebo-controlled study, conducted by the University of Roehamptom, was part of a 6-week human intervention aimed at investigating the effects of LPLDL in adults between aged 30 and 60 years with high cholesterol or hypercholesterolemia.
“High LDL cholesterol is associated with 1 in 4 heart and circulatory disease deaths in the UK, according to the latest research from the British Heart Foundation. On a global scale, cardiovascular diseases take an estimated 19 million lives each year, as reported by the British Heart Foundation,” Sofia Kolida, PhD, director of research and development at OptiBiotix, said in a statement. “This study demonstrates that LPLDL can be an effective means to support cardiovascular health, significantly improving multiple CHD risk biomarkers”.
During the study, individuals were randomly assigned to either consume 4x109 colony forming units per day of LPLDL or a placebo, both in identical delayed-release capsules. Each arm was assessed at week 3 and week 6, with those on LPLDL showing statistically significant results compared with the placebo as early as week 3.
The results of the study highlight that after taking LPLDL daily for 6 weeks, it can reduce apolipoprotein B by 28.6%, LDL by 28.4%, non-high-density lipoprotein cholesterol by 17.6%, and total cholesterol by 24.5% . These are all key CHD risk biomarkers.
“The results of this study are remarkable and firmly establish LPLDL as the probiotic for heart health. Our previous human intervention studies have highlighted LPLDL as an excellent candidate to reduce cholesterol across different patient groups and countries,” Stephen O’Hara, the CEO of OptiBiotix said in the statement. “Now with the statistically significant results of our latest study, both partners and consumers can rest assured they are using a science-backed probiotic that not only reduces total cholesterol but multiple risk factors associated with CHD.”.
LPLDL was originally isolated from vegetable juice and was discovered from a collection of more than 4000 microbial candidates by ProBiotix. The patented probiotic strain was extensively screened using the company’s OptiScreen technology platform and chosen for its ability to survive in the gut and excellent bile salt hydrolase activity.
Its established mechanism of action based on its efficacy to break down bile salts to decrease blood cholesterol means that LPLDL can help support heart health.
“Many ingredients that say they can improve heart health, often do not have sufficient scientific backing to support their claims. This latest study demonstrates the direct impact LPLDL has on multiple coronary heart disease risk biomarkers, including total cholesterol, LDL, non-HDL cholesterol, and apolipoprotein B,” Adele Costabile, PhD, a senior research associate at the University of Roehampton, said in the statement.
LPLDL from ProBiotix Health showcases statistically significant reductions in multiple coronary heart disease biomarkers in hypercholesterolemic adults. ProBiotix Health. News release. January 19, 2022. Accessed January 20, 2022. Email.